{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:38:47Z","timestamp":1771022327211,"version":"3.50.1"},"reference-count":214,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["9980"],"award-info":[{"award-number":["9980"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["2010\/2015"],"award-info":[{"award-number":["2010\/2015"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["2016\/2018"],"award-info":[{"award-number":["2016\/2018"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,2,18]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Chemoprevention is based on the use of non-toxic, pharmacologically active agents\nto prevent tumor progression. In this regard, natural dietary agents have been described by the\nmost recent literature as promising tools for controlling onset and progression of\nmalignancies. Extensive research has been so far performed to shed light on the effects of\nnatural products on tumor growth and survival, disclosing the most relevant signal\ntransduction pathways targeted by such compounds. Overall, anti-inflammatory, anti-oxidant\nand cytotoxic effects of dietary agents on tumor cells are supported either by results from\nepidemiological or animal studies and even by clinical trials.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Multiple myeloma is a hematologic malignancy characterized by abnormal proliferation of\nbone marrow plasma cells and subsequent hypercalcemia, renal dysfunction, anemia, or bone\ndisease, which remains incurable despite novel emerging therapeutic strategies. Notably,\nincreasing evidence supports the capability of dietary natural compounds to antagonize\nmultiple myeloma growth in preclinical models of the disease, underscoring their potential as\ncandidate anti-cancer agents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>In this review, we aim at summarizing findings on the anti-tumor activity of dietary natural\nproducts, focusing on their molecular mechanisms, which include inhibition of oncogenic\nsignal transduction pathways and\/or epigenetic modulating effects, along with their potential\nclinical applications against multiple myeloma and its related bone disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867325666180629153141","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T11:39:49Z","timestamp":1530272389000},"page":"187-215","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation"],"prefix":"10.2174","volume":"27","author":[{"given":"Lavinia","family":"Raimondi","sequence":"first","affiliation":[{"name":"IRCSS - Rizzoli Orthopedic Institute, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"De Luca","sequence":"additional","affiliation":[{"name":"IRCSS - Rizzoli Orthopedic Institute, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Giavaresi","sequence":"additional","affiliation":[{"name":"IRCSS - Rizzoli Orthopedic Institute, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Barone","sequence":"additional","affiliation":[{"name":"Hospice Cascina Brandezzata-Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine Catanzaro, Magna Graecia University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine Catanzaro, Magna Graecia University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Amodio","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine Catanzaro, Magna Graecia University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.29","volume":"5","author":"Allart-Vorelli P.","year":"2015","unstructured":"Allart-Vorelli P.; Porro B.; Baguet F.; Michel A.; Cousson-G\u00e9lie F.; Haematological cancer and quality of life: a systematic literature review. Blood Cancer J 2015,5(4)","journal-title":"Blood Cancer J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3322\/caac.21252","volume":"64","author":"Bianchi G.","year":"2014","unstructured":"Bianchi G.; Anderson K.C.; Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin 2014,64(6),422-444","journal-title":"CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"Rajkumar S.V.","year":"2005","unstructured":"Rajkumar S.V.; Kyle R.A.; Therneau T.M.; Melton L.J.; III; Bradwell, A.R.; Clark, R.J.; Larson, D.R.; Plevak, M.F.; Dispenzieri, A.; Katzmann, J.A. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005,106(3),812-817","journal-title":"Blood"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1517\/14712598.2013.793305","volume":"13","author":"Agnelli L.","year":"2013","unstructured":"Agnelli L.; Tassone P.; Neri A.; Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. Expert Opin Biol Ther 2013,13(Suppl. 1),S55-S68","journal-title":"Expert Opin Biol Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1182\/asheducation.V2014.1.255.3885263","volume":"2014","author":"Richardson P.G.","year":"2014","unstructured":"Richardson P.G.; Laubach J.P.; Munshi N.C.; Anderson K.C.; Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology (Am Soc Hematol Educ Program) 2014,2014(1),255-261","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.2174\/156800912802429292","volume":"12","author":"Tassone P.","year":"2012","unstructured":"Tassone P.; Neri P.; Burger R.; Di Martino M.T.; Leone E.; Amodio N.; Caraglia M.; Tagliaferri P.; Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets 2012,12(7),814-822","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/leu.2010.300","volume":"25","author":"Calimeri T.","year":"2011","unstructured":"Calimeri T.; Battista E.; Conforti F.; Neri P.; Di Martino M.T.; Rossi M.; Foresta U.; Piro E.; Ferrara F.; Amorosi A.; Bahlis N.; Anderson K.C.; Munshi N.; Tagliaferri P.; Causa F.; Tassone P.; A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011,25(4),707-711","journal-title":"Leukemia"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6504593","volume":"2016","author":"Raimondi L.","year":"2016","unstructured":"Raimondi L.; De Luca A.; Morelli E.; Giavaresi G.; Tagliaferri P.; Tassone P.; Amodio N.; MicroRNAs: Novel crossroads between myeloma cells and the bone marrow microenvironment. BioMed Res Int 2016,2016","journal-title":"BioMed Res Int"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","volume":"22","author":"Anderson K.C.","year":"2016","unstructured":"Anderson K.C.; Progress and paradigms in multiple myeloma. Clin Cancer Res 2016,22(22),5419-5427","journal-title":"Clin Cancer Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","volume":"7","author":"Hideshima T.","year":"2007","unstructured":"Hideshima T.; Mitsiades C.; Tonon G.; Richardson P.G.; Anderson K.C.; Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007,7(8),585-598","journal-title":"Nat Rev Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM198809013190901","volume":"319","author":"Vogelstein B.","year":"1988","unstructured":"Vogelstein B.; Fearon E.R.; Hamilton S.R.; Kern S.E.; Preisinger A.C.; Leppert M.; Nakamura Y.; White R.; Smits A.M.; Bos J.L.; Genetic alterations during colorectal-tumor development. N Engl J Med 1988,319(9),525-532","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1289\/ehp.931009","volume":"100","author":"Barrett J.C.","year":"1993","unstructured":"Barrett J.C.; Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect 1993,100,9-20","journal-title":"Environ Health Perspect"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-3-319-31254-5_3","author":"Amodio N.","year":"2016","unstructured":"Amodio N.; Morelli E.; Barone A.; Tassone P.;  Challenges in multiple myeloma chemoprevention: potential role of natural, synthetic and endogenous molecules in: Molecular Targets and Strategies in Cancer Prevention 2016,37-60","journal-title":"Challenges in multiple myeloma chemoprevention: potential role of natural, synthetic and endogenous molecules in: Molecular Targets and Strategies in Cancer Prevention"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2018.02.025","volume":"422","author":"Chhabra G.","year":"2018","unstructured":"Chhabra G.; Singh C.K.; Ndiaye M.A.; Fedorowicz S.; Molot A.; Ahmad N.; Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications. Cancer Lett 2018,422,9-18","journal-title":"Cancer Lett"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/01635581.2012.630551","volume":"64","author":"Sung B.","year":"2012","unstructured":"Sung B.; Prasad S.; Yadav V.R.; Aggarwal B.B.; Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr Cancer 2012,64(2),173-197","journal-title":"Nutr Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1021\/mp500054h","volume":"11","author":"Niu Y.","year":"2014","unstructured":"Niu Y.; Bai J.; Kamm R.D.; Wang Y.; Wang C.; Validating antimetastatic effects of natural products in an engineered microfluidic platform mimicking tumor microenvironment. Mol Pharm 2014,11(7),2022-2029","journal-title":"Mol Pharm"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-017-0663-5","volume":"37","author":"De Luca A.","year":"2018","unstructured":"De Luca A.; Raimondi L.; Salamanna F.; Carina V.; Costa V.; Bellavia D.; Alessandro R.; Fini M.; Giavaresi G.; Relevance of 3d culture systems to study osteosarcoma environment. J Exp Clin Cancer Res 2018,37(1),2","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.exphem.2011.06.007","volume":"39","author":"Wang F.M.","year":"2011","unstructured":"Wang F.M.; Galson D.L.; Roodman G.D.; Ouyang H.; Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Exp Hematol 2011,39(10),999-1006","journal-title":"Exp Hematol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3324\/haematol.2010.029363","volume":"96","author":"Jakubikova J.","year":"2011","unstructured":"Jakubikova J.; Cervi D.; Ooi M.; Kim K.; Nahar S.; Klippel S.; Cholujova D.; Leiba M.; Daley J.F.; Delmore J.; Negri J.; Blotta S.; McMillin D.W.; Hideshima T.; Richardson P.G.; Sedlak J.; Anderson K.C.; Mitsiades C.S.; Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. Haematologica 2011,96(8),1170-1179","journal-title":"Haematologica"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrg3230","volume":"13","author":"Jones P.A.","year":"2012","unstructured":"Jones P.A.; Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012,13(7),484-492","journal-title":"Nat Rev Genet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/hmg\/9.16.2395","volume":"9","author":"Bestor T.H.","year":"2000","unstructured":"Bestor T.H.; The DNA methyltransferases of mammals. Hum Mol Genet 2000,9(16),2395-2402","journal-title":"Hum Mol Genet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/sj.leu.2403434","volume":"18","author":"Galm O.","year":"2004","unstructured":"Galm O.; Wilop S.; Reichelt J.; Jost E.; Gehbauer G.; Herman J.G.; Osieka R.; DNA methylation changes in multiple myeloma. Leukemia 2004,18(10),1687-1692","journal-title":"Leukemia"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1039\/b703830p","volume":"37","author":"Bieliauskas A.V.","year":"2008","unstructured":"Bieliauskas A.V.; Pflum M.K.; Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 2008,37(7),1402-1413","journal-title":"Chem Soc Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1365-2141.2008.07387.x","volume":"143","author":"Neri P.","year":"2008","unstructured":"Neri P.; Tagliaferri P.; Di Martino M.T.; Calimeri T.; Amodio N.; Bulotta A.; Ventura M.; Eramo P.O.; Viscomi C.; Arbitrio M.; Rossi M.; Caraglia M.; Munshi N.C.; Anderson K.C.; Tassone P.; \n                        In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 2008,143(4),520-531","journal-title":"Br J Haematol"},{"key":"ref=25","first-page":"363","volume":"23","author":"Aggarwal B.B.","year":"2003","unstructured":"Aggarwal B.B.; Kumar A.; Bharti A.C.; Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003,23(1A),363-398","journal-title":"Anticancer Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00432-008-0461-8","volume":"135","author":"von Metzler I.","year":"2009","unstructured":"von Metzler I.; Krebbel H.; Kuckelkorn U.; Heider U.; Jakob C.; Kaiser M.; Fleissner C.; Terpos E.; Sezer O.; Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase. J Cancer Res Clin Oncol 2009,135(2),173-179","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.canlet.2008.03.009","volume":"269","author":"Kunnumakkara A.B.","year":"2008","unstructured":"Kunnumakkara A.B.; Anand P.; Aggarwal B.B.; Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008,269(2),199-225","journal-title":"Cancer Lett"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/1535-7163.MCT-08-0905","volume":"8","author":"Sung B.","year":"2009","unstructured":"Sung B.; Kunnumakkara A.B.; Sethi G.; Anand P.; Guha S.; Aggarwal B.B.; Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009,8(4),959-970","journal-title":"Mol Cancer Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tiv.2017.12.001","volume":"47","author":"Allegra A.","year":"2018","unstructured":"Allegra A.; Speciale A.; Molonia M.S.; Guglielmo L.; Musolino C.; Ferlazzo G.; Costa G.; Saija A.; Cimino F.; Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-\u03baB pathways. Toxicol In Vitro 2018,47,186-194","journal-title":"Toxicol In Vitro"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4161\/15384047.2014.986997","volume":"16","author":"Gomez-Bougie P.","year":"2015","unstructured":"Gomez-Bougie P.; Halliez M.; Ma\u00efga S.; Godon C.; Kervo\u00eblen C.; Pellat-Deceunynck C.; Moreau P.; Amiot M.; Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Cancer Biol Ther 2015,16(1),60-65","journal-title":"Cancer Biol Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"100831","DOI":"10.18632\/oncotarget.19852","volume":"8","author":"Raimondi L.","year":"2017","unstructured":"Raimondi L.; De Luca A.; Costa V.; Amodio N.; Carina V.; Bellavia D.; Tassone P.; Pagani S.; Fini M.; Alessandro R.; Giavaresi G.; Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. Oncotarget 2017,8(59),100831-100851","journal-title":"Oncotarget"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1517\/14712598.2013.796356","volume":"13","author":"Amodio N.","year":"2013","unstructured":"Amodio N.; Di Martino M.T.; Neri A.; Tagliaferri P.; Tassone P.; Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther 2013,13(Suppl. 1),S125-S137","journal-title":"Expert Opin Biol Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.18632\/oncotarget.6151","volume":"7","author":"Calura E.","year":"2016","unstructured":"Calura E.; Bisognin A.; Manzoni M.; Todoerti K.; Taiana E.; Sales G.; Morgan G.J.; Tonon G.; Amodio N.; Tassone P.; Neri A.; Agnelli L.; Romualdi C.; Bortoluzzi S.; Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. Oncotarget 2016,7(3),2367-2378","journal-title":"Oncotarget"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.3390\/genes9020069","volume":"9","author":"Nobili L.","year":"2018","unstructured":"Nobili L.; Ronchetti D.; Agnelli L.; Taiana E.; Vinci C.; Neri A.; Long non-coding RNAs in multiple myeloma. Genes (Basel) 2018,9(2)","journal-title":"Genes (Basel)"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14728222.2016.1266339","volume":"21","author":"Amodio N.","year":"2017","unstructured":"Amodio N.; D\u2019Aquila P.; Passarino G.; Tassone P.; Bellizzi D.; Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. Expert Opin Ther Targets 2017,21(1),91-101","journal-title":"Expert Opin Ther Targets"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1038\/s41375-018-0067-3","volume":"32","author":"Amodio N.","year":"2018","unstructured":"Amodio N.; Stamato M.A.; Juli G.; Morelli E.; Fulciniti M.; Manzoni M.; Taiana E.; Agnelli L.; Cantafio M.E.G.; Romeo E.; Raimondi L.; Caracciolo D.; Zuccal\u00e0 V.; Rossi M.; Neri A.; Munshi N.C.; Tagliaferri P.; Tassone P.; Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia 2018,32(9),1948-1957","journal-title":"Leukemia"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-018-0606-4","volume":"11","author":"Amodio N.","year":"2018","unstructured":"Amodio N.; Raimondi L.; Juli G.; Stamato M.A.; Caracciolo D.; Tagliaferri P.; Tassone P.; MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol 2018,11(1),63","journal-title":"J Hematol Oncol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-12-3325","volume":"19","author":"Leone E.","year":"2013","unstructured":"Leone E.; Morelli E.; Di Martino M.T.; Amodio N.; Foresta U.; Gull\u00e0 A.; Rossi M.; Neri A.; Giordano A.; Munshi N.C.; Anderson K.C.; Tagliaferri P.; Tassone P.; Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013,19(8),2096-2106","journal-title":"Clin Cancer Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"27343","DOI":"10.18632\/oncotarget.4398","volume":"6","author":"Pitari M.R.","year":"2015","unstructured":"Pitari M.R.; Rossi M.; Amodio N.; Botta C.; Morelli E.; Federico C.; Gull\u00e0 A.; Caracciolo D.; Di Martino M.T.; Arbitrio M.; Giordano A.; Tagliaferri P.; Tassone P.; Inhibition of miR-21 restores RANKL\/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. Oncotarget 2015,6(29),27343-27358","journal-title":"Oncotarget"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1158\/1078-0432.CCR-15-0489","volume":"22","author":"Gull\u00e0 A.","year":"2016","unstructured":"Gull\u00e0 A.; Di Martino M.T.; Gallo Cantafio M.E.; Morelli E.; Amodio N.; Botta C.; Pitari M.R.; Lio S.G.; Britti D.; Stamato M.A.; Hideshima T.; Munshi N.C.; Anderson K.C.; Tagliaferri P.; Tassone P.A.; 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells. Clin Cancer Res 2016,22(5),1222-1233","journal-title":"Clin Cancer Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/jcp.24669","volume":"229","author":"Leotta M.","year":"2014","unstructured":"Leotta M.; Biamonte L.; Raimondi L.; Ronchetti D.; Di Martino M.T.; Botta C.; Leone E.; Pitari M.R.; Neri A.; Giordano A.; Tagliaferri P.; Tassone P.; Amodio N.A.; p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. J Cell Physiol 2014,229(12),2106-2116","journal-title":"J Cell Physiol"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.36","volume":"5","author":"Gallo Cantafio M.E.","year":"2016","unstructured":"Gallo Cantafio M.E.; Nielsen B.S.; Mignogna C.; Arbitrio M.; Botta C.; Frandsen N.M.; Rolfo C.; Tagliaferri P.; Tassone P.; Di Martino M.T.; Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates. Mol Ther Nucleic Acids 2016,5(6)","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"17949","DOI":"10.1038\/s41598-017-18186-0","volume":"7","author":"Zarone M.R.","year":"2017","unstructured":"Zarone M.R.; Misso G.; Grimaldi A.; Zappavigna S.; Russo M.; Amler E.; Di Martino M.T.; Amodio N.; Tagliaferri P.; Tassone P.; Caraglia M.; Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. Sci Rep 2017,7(1),17949","journal-title":"Sci Rep"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"12837","DOI":"10.18632\/oncotarget.3805","volume":"6","author":"Amodio N.","year":"2015","unstructured":"Amodio N.; Rossi M.; Raimondi L.; Pitari M.R.; Botta C.; Tagliaferri P.; Tassone P.; miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget 2015,6(15),12837-12861","journal-title":"Oncotarget"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/1535-7163.MCT-15-0985","volume":"15","author":"Amodio N.","year":"2016","unstructured":"Amodio N.; Stamato M.A.; Gull\u00e0 A.M.; Morelli E.; Romeo E.; Raimondi L.; Pitari M.R.; Ferrandino I.; Misso G.; Caraglia M.; Perrotta I.; Neri A.; Fulciniti M.; Rolfo C.; Anderson K.C.; Munshi N.C.; Tagliaferri P.; Tassone P.; Therapeutic targeting of miR-29b\/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther 2016,15(6),1364-1375","journal-title":"Mol Cancer Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"106527","DOI":"10.18632\/oncotarget.22507","volume":"8","author":"Stamato M.A.","year":"2017","unstructured":"Stamato M.A.; Juli G.; Romeo E.; Ronchetti D.; Arbitrio M.; Caracciolo D.; Neri A.; Tagliaferri P.; Tassone P.; Amodio N.; Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. Oncotarget 2017,8(63),106527-106537","journal-title":"Oncotarget"},{"key":"ref=47","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.106","volume":"6","author":"Fulciniti M.","year":"2016","unstructured":"Fulciniti M.; Amodio N.; Bandi R.L.; Cagnetta A.; Samur M.K.; Acharya C.; Prabhala R.; D\u2019Aquila P.; Bellizzi D.; Passarino G.; Adamia S.; Neri A.; Hunter Z.R.; Treon S.P.; Anderson K.C.; Tassone P.; Munshi N.C.; miR-23b\/SP1\/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J 2016,6","journal-title":"Blood Cancer J"},{"key":"ref=48","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.175","volume":"3","author":"Amodio N.","year":"2012","unstructured":"Amodio N.; Di Martino M.T.; Foresta U.; Leone E.; Lionetti M.; Leotta M.; Gull\u00e0 A.M.; Pitari M.R.; Conforti F.; Rossi M.; Agosti V.; Fulciniti M.; Misso G.; Morabito F.; Ferrarini M.; Neri A.; Caraglia M.; Munshi N.C.; Anderson K.C.; Tagliaferri P.; Tassone P.; miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 2012,3","journal-title":"Cell Death Dis"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.4161\/cc.26585","volume":"12","author":"Amodio N.","year":"2013","unstructured":"Amodio N.; Bellizzi D.; Leotta M.; Raimondi L.; Biamonte L.; D\u2019Aquila P.; Di Martino M.T.; Calimeri T.; Rossi M.; Lionetti M.; Leone E.; Passarino G.; Neri A.; Giordano A.; Tagliaferri P.; Tassone P.; miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle 2013,12(23),3650-3662","journal-title":"Cell Cycle"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/leu.2017.336","volume":"32","author":"Botta C.","year":"2018","unstructured":"Botta C.; Cuc\u00e8 M.; Pitari M.R.; Caracciolo D.; Gull\u00e0 A.; Morelli E.; Riillo C.; Biamonte L.; Gallo Cantafio M.E.; Prabhala R.; Mignogna C.; Di Vito A.; Altomare E.; Amodio N.; Di Martino M.T.; Correale P.; Rossi M.; Giordano A.; Munshi N.C.; Tagliaferri P.; Tassone P.; MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia 2018,32(4),1003-1015","journal-title":"Leukemia"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"564","DOI":"10.2174\/1381612823666170317164639","volume":"24","author":"Wu C.","year":"2018","unstructured":"Wu C.; Ruan T.; Liu W.; Zhu X.; Pan J.; Lu W.; Yan C.; Tao K.; Zhang W.; Zhang C.; Effect and mechanism of curcumin on EZH2 - miR-101 regulatory feedback loop in multiple myeloma. Curr Pharm Des 2018,24(5),564-575","journal-title":"Curr Pharm Des"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3892\/or.2015.4467","volume":"35","author":"Huang D.","year":"2016","unstructured":"Huang D.; Wang X.; Zhuang C.; Shi W.; Liu M.; Tu Q.; Zhang D.; Hu L.; Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma. Oncol Rep 2016,35(2),1083-1090","journal-title":"Oncol Rep"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.4049\/jimmunol.172.10.5940","volume":"172","author":"Bharti A.C.","year":"2004","unstructured":"Bharti A.C.; Takada Y.; Aggarwal B.B.; Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004,172(10),5940-5947","journal-title":"J Immunol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"5917","DOI":"10.1158\/1078-0432.CCR-08-2217","volume":"15","author":"Golombick T.","year":"2009","unstructured":"Golombick T.; Diamond T.H.; Badmaev V.; Manoharan A.; Ramakrishna R.; The potential role of curcumin in patients with monoclonal gammopathy of undefined significance--its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res 2009,15(18),5917-5922","journal-title":"Clin Cancer Res"},{"key":"ref=55","first-page":"5145","volume":"30","author":"Bang M.H.","year":"2010","unstructured":"Bang M.H.; Van Riep T.; Thinh N.T.; Song H.; Dung T.T.; Van Truong L.; Van Don L.; Ky T.D.; Pan D.; Shaheen M.; Ghoneum M.; Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial. Anticancer Res 2010,30(12),5145-5151","journal-title":"Anticancer Res"},{"key":"ref=56","first-page":"81","volume":"34","author":"Ghoneum M.","year":"2014","unstructured":"Ghoneum M.; Badr El-Din N.K.; Ali D.A.; El-Dein M.A.; Modified arabinoxylan from rice bran, MGN-3\/biobran, sensitizes metastatic breast cancer cells to paclitaxel in vitro. Anticancer Res 2014,34(1),81-87","journal-title":"Anticancer Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0304-3835(03)00458-0","volume":"201","author":"Ghoneum M.","year":"2003","unstructured":"Ghoneum M.; Gollapudi S.; Modified arabinoxylan rice bran (MGN-3\/Biobran) sensitizes human T cell leukemia cells to death receptor (CD95)-induced apoptosis. Cancer Lett 2003,201(1),41-49","journal-title":"Cancer Lett"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4149\/neo_2011_02_118","volume":"58","author":"Ghoneum M.","year":"2011","unstructured":"Ghoneum M.; Gollapudi S.; Synergistic apoptotic effect of arabinoxylan rice bran (MGN-3\/Biobran) and curcumin (turmeric) on human multiple myeloma cell line U266 in vitro. Neoplasma 2011,58(2),118-123","journal-title":"Neoplasma"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/1534735416635742","volume":"15","author":"Golombick T.","year":"2016","unstructured":"Golombick T.; Diamond T.H.; Manoharan A.; Ramakrishna R.; Addition of rice bran arabinoxylan to curcumin therapy may be of benefit to patients with early-stage b-cell lymphoid malignancies (monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or stage 0\/1 chronic lymphocytic leukemia): A preliminary clinical study. Integr Cancer Ther 2016,15(2),183-189","journal-title":"Integr Cancer Ther"},{"key":"ref=60","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-218148","volume":"2017","author":"Zaidi A.","year":"2017","unstructured":"Zaidi A.; Lai M.; Cavenagh J.; Long-term stabilisation of myeloma with curcumin. BMJ Case Rep 2017,2017","journal-title":"BMJ Case Rep"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1126\/science.275.5297.218","volume":"275","author":"Jang M.","year":"1997","unstructured":"Jang M.; Cai L.; Udeani G.O.; Slowing K.V.; Thomas C.F.; Beecher C.W.; Fong H.H.; Farnsworth N.R.; Kinghorn A.D.; Mehta R.G.; Moon R.C.; Pezzuto J.M.; Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997,275(5297),218-220","journal-title":"Science"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2010.05870.x","volume":"1215","author":"Shukla Y.","year":"2011","unstructured":"Shukla Y.; Singh R.; Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci 2011,1215,1-8","journal-title":"Ann N Y Acad Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.mrfmmm.2004.05.019","volume":"555","author":"Kundu J.K.","year":"2004","unstructured":"Kundu J.K.; Surh Y.J.; Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat Res 2004,555(1-2),65-80","journal-title":"Mutat Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1182\/blood-2006-02-003988","volume":"109","author":"Bhardwaj A.","year":"2007","unstructured":"Bhardwaj A.; Sethi G.; Vadhan-Raj S.; Bueso-Ramos C.; Takada Y.; Gaur U.; Nair A.S.; Shishodia S.; Aggarwal B.B.; Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007,109(6),2293-2302","journal-title":"Blood"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/j.1745-7254.2006.00343.x","volume":"27","author":"Sun C.Y.","year":"2006","unstructured":"Sun C.Y.; Hu Y.; Guo T.; Wang H.F.; Zhang X.P.; He W.J.; Tan H.; Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity. Acta Pharmacol Sin 2006,27(11),1447-1452","journal-title":"Acta Pharmacol Sin"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"9943","DOI":"10.1158\/0008-5472.CAN-05-0651","volume":"65","author":"Boissy P.","year":"2005","unstructured":"Boissy P.; Andersen T.L.; Abdallah B.M.; Kassem M.; Plesner T.; Delaiss\u00e9 J.M.; Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005,65(21),9943-9952","journal-title":"Cancer Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-015-1693-z","volume":"15","author":"Kala R.","year":"2015","unstructured":"Kala R.; Shah H.N.; Martin S.L.; Tollefsbol T.O.; Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent \u03b3-H2AX and telomerase regulation in triple-negative breast cancer. BMC Cancer 2015,15,672","journal-title":"BMC Cancer"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"39363","DOI":"10.18632\/oncotarget.8101","volume":"7","author":"Huang W.C.","year":"2016","unstructured":"Huang W.C.; Chan M.L.; Chen M.J.; Tsai T.H.; Chen Y.J.; Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene. Oncotarget 2016,7(26),39363-39375","journal-title":"Oncotarget"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"27214","DOI":"10.18632\/oncotarget.4877","volume":"6","author":"Dhar S.","year":"2015","unstructured":"Dhar S.; Kumar A.; Rimando A.M.; Zhang X.; Levenson A.S.; Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer. Oncotarget 2015,6(29),27214-27226","journal-title":"Oncotarget"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1089\/ars.2015.6437","volume":"24","author":"Benlloch M.","year":"2016","unstructured":"Benlloch M.; Obrador E.; Valles S.L.; Rodriguez M.L.; Sirerol J.A.; Alc\u00e1cer J.; Pellicer J.A.; Salvador R.; Cerd\u00e1 C.; S\u00e1ez G.T.; Estrela J.M.; Pterostilbene decreases the antioxidant defenses of aggressive cancer cells in vivo: A physiological glucocorticoids- and Nrf2-dependent mechanism. Antioxid Redox Signal 2016,24(17),974-990","journal-title":"Antioxid Redox Signal"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17111927","volume":"17","author":"Xie B.","year":"2016","unstructured":"Xie B.; Xu Z.; Hu L.; Chen G.; Wei R.; Yang G.; Li B.; Chang G.; Sun X.; Wu H.; Zhang Y.; Dai B.; Tao Y.; Shi J.; Zhu W.; Pterostilbene inhibits human multiple myeloma cells via erk1\/2 and jnk pathway in vitro and in vivo. Int J Mol Sci 2016,17(11)","journal-title":"Int J Mol Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3892\/or.2017.5675","volume":"38","author":"Chen G.","year":"2017","unstructured":"Chen G.; Xu Z.; Chang G.; Hou J.; Hu L.; Zhang Y.; Yu D.; Li B.; Chang S.; Xie Y.; Zhang Y.; Wei R.; Wu H.; Xiao W.; Sun X.; Tao Y.; Gao L.; Dai B.; Shi J.; Zhu W.; The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells. Oncol Rep 2017,38(1),488-496","journal-title":"Oncol Rep"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"420","DOI":"10.7164\/antibiotics.23.420","volume":"23","author":"Katagiri K.","year":"1970","unstructured":"Katagiri K.; Sato K.; Hayakawa S.; Matsushima T.; Minato H.; Verticillin A.; Verticillin A, a new antibiotic from Verticillium sp. J Antibiot (Tokyo) 1970,23(8),420-422","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=74","first-page":"213","volume":"8","author":"Neuss N.","year":"1968","unstructured":"Neuss N.; Boeck L.D.; Brannon D.R.; Cline J.C.; DeLong D.C.; Gorman M.; Huckstep L.L.; Lively D.H.; Mabe J.; Marsh M.M.; Molloy B.B.; Nagarajan R.; Nelson J.D.; Stark W.M.; Aranotin and related metabolites from Arachniotus aureus (Eidam) Schroeter. IV. Fermentation, isolation, structure elucidation, biosynthesis, and antiviral properties. Antimicrob Agents Chemother 1968,8,213-219","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0165-2478(99)00155-8","volume":"71","author":"Yamada A.","year":"2000","unstructured":"Yamada A.; Kataoka T.; Nagai K.; The fungal metabolite gliotoxin: immunosuppressive activity on CTL-mediated cytotoxicity. Immunol Lett 2000,71(1),27-32","journal-title":"Immunol Lett"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1248\/cpb.52.1018","volume":"52","author":"Kawahara N.","year":"2004","unstructured":"Kawahara N.; Kurata A.; Hakamatsuka T.; Sekita S.; Satake M.; Two new cucurbitacin glucosides, opercurins A and B, from the Brazilian folk medicine \u201cBuchinha\u201d (Luffa operculata). Chem Pharm Bull (Tokyo) 2004,52(8),1018-1020","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1385\/MO:21:1:21","volume":"21","author":"Vigushin D.M.","year":"2004","unstructured":"Vigushin D.M.; Mirsaidi N.; Brooke G.; Sun C.; Pace P.; Inman L.; Moody C.J.; Coombes R.C.; Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. Med Oncol 2004,21(1),21-30","journal-title":"Med Oncol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2006-07-027326","volume":"109","author":"Isham C.R.","year":"2007","unstructured":"Isham C.R.; Tibodeau J.D.; Jin W.; Xu R.; Timm M.M.; Bible K.C.; Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 2007,109(6),2579-2588","journal-title":"Blood"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"46047","DOI":"10.18632\/oncotarget.17517","volume":"8","author":"Vo M.C.","year":"2017","unstructured":"Vo M.C.; Nguyen-Pham T.N.; Lee H.J.; Jung S.H.; Choi N.R.; Hoang M.D.; Kim H.J.; Lee J.J.; Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells. Oncotarget 2017,8(28),46047-46056","journal-title":"Oncotarget"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.nutr.23.011702.073102","volume":"23","author":"Urizar N.L.","year":"2003","unstructured":"Urizar N.L.; Moore D.D.; GUGULIPID: a natural cholesterol-lowering agent. Annu Rev Nutr 2003,23,303-313","journal-title":"Annu Rev Nutr"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1043-2760(02)00640-9","volume":"13","author":"Sinal C.J.","year":"2002","unstructured":"Sinal C.J.; Gonzalez F.J.; Guggulsterone: an old approach to a new problem. Trends Endocrinol Metab 2002,13(7),275-276","journal-title":"Trends Endocrinol Metab"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-05-0223","volume":"4","author":"Singh S.V.","year":"2005","unstructured":"Singh S.V.; Zeng Y.; Xiao D.; Vogel V.G.; Nelson J.B.; Dhir R.; Tripathi Y.B.; Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak. Mol Cancer Ther 2005,4(11),1747-1754","journal-title":"Mol Cancer Ther"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.1158\/0008-5472.CAN-07-0120","volume":"67","author":"Singh S.V.","year":"2007","unstructured":"Singh S.V.; Choi S.; Zeng Y.; Hahm E.R.; Xiao D.; Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. Cancer Res 2007,67(15),7439-7449","journal-title":"Cancer Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1158\/0008-5472.CAN-07-6696","volume":"68","author":"Ahn K.S.","year":"2008","unstructured":"Ahn K.S.; Sethi G.; Sung B.; Goel A.; Ralhan R.; Aggarwal B.B.; Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res 2008,68(11),4406-4415","journal-title":"Cancer Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/1078-0432.CCR-05-1749","volume":"12","author":"Ichikawa H.","year":"2006","unstructured":"Ichikawa H.; Aggarwal B.B.; Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation. Clin Cancer Res 2006,12(2),662-668","journal-title":"Clin Cancer Res"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.bbrc.2004.07.186","volume":"322","author":"Pinna G.F.","year":"2004","unstructured":"Pinna G.F.; Fiorucci M.; Reimund J.M.; Taquet N.; Arondel Y.; Muller C.D.; Celastrol inhibits pro-inflammatory cytokine secretion in Crohn\u2019s disease biopsies. Biochem Biophys Res Commun 2004,322(3),778-786","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0278-5846(01)00192-0","volume":"25","author":"Allison A.C.","year":"2001","unstructured":"Allison A.C.; Cacabelos R.; Lombardi V.R.; Alvarez X.A.; Vigo C.; Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 2001,25(7),1341-1357","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1182\/blood-2006-10-050807","volume":"109","author":"Sethi G.","year":"2007","unstructured":"Sethi G.; Ahn K.S.; Pandey M.K.; Aggarwal B.B.; Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007,109(7),2727-2735","journal-title":"Blood"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1476-5381.2011.01449.x","volume":"164","author":"Kannaiyan R.","year":"2011","unstructured":"Kannaiyan R.; Hay H.S.; Rajendran P.; Li F.; Shanmugam M.K.; Vali S.; Abbasi T.; Kapoor S.; Sharma A.; Kumar A.P.; Chng W.J.; Sethi G.; Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-\u03baB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol 2011,164(5),1506-1521","journal-title":"Br J Pharmacol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.canlet.2008.01.043","volume":"264","author":"Huang Y.","year":"2008","unstructured":"Huang Y.; Zhou Y.; Fan Y.; Zhou D.; Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 2008,264(1),101-106","journal-title":"Cancer Lett"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.canlet.2009.09.006","volume":"290","author":"Lu Z.","year":"2010","unstructured":"Lu Z.; Jin Y.; Qiu L.; Lai Y.; Pan J.; Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett 2010,290(2),182-191","journal-title":"Cancer Lett"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-09-3201","volume":"70","author":"Pang X.","year":"2010","unstructured":"Pang X.; Yi Z.; Zhang J.; Lu B.; Sung B.; Qu W.; Aggarwal B.B.; Liu M.; Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT\/mammalian target of rapamycin pathway. Cancer Res 2010,70(5),1951-1959","journal-title":"Cancer Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3892\/ijo.2011.1161","volume":"39","author":"Tozawa K.","year":"2011","unstructured":"Tozawa K.; Sagawa M.; Kizaki M.; Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-\u03baB pathway. Int J Oncol 2011,39(5),1117-1122","journal-title":"Int J Oncol"},{"key":"ref=94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095846","volume":"9","author":"Ni H.","year":"2014","unstructured":"Ni H.; Zhao W.; Kong X.; Li H.; Ouyang J.; NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis. PLoS One 2014,9(4)","journal-title":"PLoS One"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/abbs\/gmx021","volume":"49","author":"Hu L.","year":"2017","unstructured":"Hu L.; Wu H.; Li B.; Song D.; Yang G.; Chen G.; Xie B.; Xu Z.; Zhang Y.; Yu D.; Hou J.; Xiao W.; Sun X.; Chang G.; Zhang Y.; Gao L.; Dai B.; Tao Y.; Shi J.; Zhu W.; Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1\/2 and IL-6\/STAT3 pathways in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai) 2017,49(5),420-427","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref=96","first-page":"950","volume":"17","author":"Khader M.","year":"2014","unstructured":"Khader M.; Eckl P.M.; Thymoquinone: an emerging natural drug with a wide range of medical applications. Iran J Basic Med Sci 2014,17(12),950-957","journal-title":"Iran J Basic Med Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.bcp.2011.09.029","volume":"83","author":"Woo C.C.","year":"2012","unstructured":"Woo C.C.; Kumar A.P.; Sethi G.; Tan K.H.; Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol 2012,83(4),443-451","journal-title":"Biochem Pharmacol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1476-5381.2010.00874.x","volume":"161","author":"Li F.","year":"2010","unstructured":"Li F.; Rajendran P.; Sethi G.; Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol 2010,161(3),541-554","journal-title":"Br J Pharmacol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1349-7006.2005.00062.x","volume":"96","author":"Yamazaki D.","year":"2005","unstructured":"Yamazaki D.; Kurisu S.; Takenawa T.; Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005,96(7),379-386","journal-title":"Cancer Sci"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/1476-511X-10-236","volume":"10","author":"Badr G.","year":"2011","unstructured":"Badr G.; Mohany M.; Abu-Tarboush F.; Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2\/Bcl-XL expression. Lipids Health Dis 2011,10,236","journal-title":"Lipids Health Dis"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"9536","DOI":"10.1074\/jbc.M211803200","volume":"278","author":"Fernandis A.Z.","year":"2003","unstructured":"Fernandis A.Z.; Cherla R.P.; Ganju R.K.; Differential regulation of CXCR4-mediated T-cell chemotaxis and mitogen-activated protein kinase activation by the membrane tyrosine phosphatase, CD45. J Biol Chem 2003,278(11),9536-9543","journal-title":"J Biol Chem"},{"key":"ref=102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023741","volume":"6","author":"Badr G.","year":"2011","unstructured":"Badr G.; Lefevre E.A.; Mohany M.; Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS One 2011,6(9)","journal-title":"PLoS One"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"634","DOI":"10.18632\/oncotarget.1596","volume":"5","author":"Siveen K.S.","year":"2014","unstructured":"Siveen K.S.; Mustafa N.; Li F.; Kannaiyan R.; Ahn K.S.; Kumar A.P.; Chng W.J.; Sethi G.; Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-\u03baB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget 2014,5(3),634-648","journal-title":"Oncotarget"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/aps.2009.50","volume":"30","author":"Wu X.","year":"2009","unstructured":"Wu X.; Zhou Q.H.; Xu K.; Are isothiocyanates potential anti-cancer drugs? Acta Pharmacol Sin 2009,30(5),501-512","journal-title":"Acta Pharmacol Sin"},{"key":"ref=105","first-page":"1976s","volume":"54","author":"Zhang Y.","year":"1994","unstructured":"Zhang Y.; Talalay P.; Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res 1994,54(7)(Suppl.),1976s-1981s","journal-title":"Cancer Res"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/jcb.240590825","volume":"22","author":"Hecht S.S.","year":"1995","unstructured":"Hecht S.S.; Chemoprevention by isothiocyanates. J Cell Biochem Suppl 1995,22,195-209","journal-title":"J Cell Biochem Suppl"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/carcin\/bgq242","volume":"32","author":"Mi L.","year":"2011","unstructured":"Mi L.; Gan N.; Chung F.L.; Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells. Carcinogenesis 2011,32(2),216-223","journal-title":"Carcinogenesis"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.bcp.2009.12.008","volume":"79","author":"Brunelli D.","year":"2010","unstructured":"Brunelli D.; Tavecchio M.; Falcioni C.; Frapolli R.; Erba E.; Iori R.; Rollin P.; Barillari J.; Manzotti C.; Morazzoni P.; D\u2019Incalci M.; The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo. Biochem Pharmacol 2010,79(8),1141-1148","journal-title":"Biochem Pharmacol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1756-8722-1-6","volume":"1","author":"Lu Q.","year":"2008","unstructured":"Lu Q.; Lin X.; Feng J.; Zhao X.; Gallagher R.; Lee M.Y.; Chiao J.W.; Liu D.; Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol 2008,1,6","journal-title":"J Hematol Oncol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1006\/bbrc.2002.6622","volume":"292","author":"Nakagawa H.","year":"2002","unstructured":"Nakagawa H.; Wachi M.; Woo J.T.; Kato M.; Kasai S.; Takahashi F.; Lee I.S.; Nagai K.; Fenton reaction is primarily involved in a mechanism of (-)-epigallocatechin-3-gallate to induce osteoclastic cell death. Biochem Biophys Res Commun 2002,292(1),94-101","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1600-0765.2004.00743.x","volume":"39","author":"Yun J.H.","year":"2004","unstructured":"Yun J.H.; Pang E.K.; Kim C.S.; Yoo Y.J.; Cho K.S.; Chai J.K.; Kim C.K.; Choi S.H.; Inhibitory effects of green tea polyphenol (-)-epigallocatechin gallate on the expression of matrix metalloproteinase-9 and on the formation of osteoclasts. J Periodontal Res 2004,39(5),300-307","journal-title":"J Periodontal Res"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jnutbio.2006.06.005","volume":"18","author":"Vali B.","year":"2007","unstructured":"Vali B.; Rao L.G.; El-Sohemy A.; Epigallocatechin-3-gallate increases the formation of mineralized bone nodules by human osteoblast-like cells. J Nutr Biochem 2007,18(5),341-347","journal-title":"J Nutr Biochem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"8773","DOI":"10.1021\/jf300671j","volume":"60","author":"Tom\u00e1s-Barber\u00e1n F.A.","year":"2012","unstructured":"Tom\u00e1s-Barber\u00e1n F.A.; Andr\u00e9s-Lacueva C.; Polyphenols and health: current state and progress. J Agric Food Chem 2012,60(36),8773-8775","journal-title":"J Agric Food Chem"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/ejcn.2013.29","volume":"67","author":"Kishimoto Y.","year":"2013","unstructured":"Kishimoto Y.; Tani M.; Kondo K.; Pleiotropic preventive effects of dietary polyphenols in cardiovascular diseases. Eur J Clin Nutr 2013,67(5),532-535","journal-title":"Eur J Clin Nutr"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/21551197.2012.698219","volume":"31","author":"Corcoran M.P.","year":"2012","unstructured":"Corcoran M.P.; McKay D.L.; Blumberg J.B.; Flavonoid basics: chemistry, sources, mechanisms of action, and safety. J Nutr Gerontol Geriatr 2012,31(3),176-189","journal-title":"J Nutr Gerontol Geriatr"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1182\/blood-2008-07-171389","volume":"113","author":"Golden E.B.","year":"2009","unstructured":"Golden E.B.; Lam P.Y.; Kardosh A.; Gaffney K.J.; Cadenas E.; Louie S.G.; Petasis N.A.; Chen T.C.; Sch\u00f6nthal A.H.; Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009,113(23),5927-5937","journal-title":"Blood"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/abbs\/gmp094","volume":"41","author":"Wang Q.","year":"2009","unstructured":"Wang Q.; Li J.; Gu J.; Huang B.; Zhao Y.; Zheng D.; Ding Y.; Zeng L.; Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells. Acta Biochim Biophys Sin (Shanghai) 2009,41(12),1018-1026","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1054\/bjoc.2001.2078","volume":"85","author":"Vande Broek I.","year":"2001","unstructured":"Vande Broek I.; Vanderkerken K.; De Greef C.; Asosingh K.; Straetmans N.; Van Camp B.; Van Riet I.; Laminin-1-induced migration of multiple myeloma cells involves the high-affinity 67 kD laminin receptor. Br J Cancer 2001,85(9),1387-1395","journal-title":"Br J Cancer"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2006-05-022814","volume":"108","author":"Shammas M.A.","year":"2006","unstructured":"Shammas M.A.; Neri P.; Koley H.; Batchu R.B.; Bertheau R.C.; Munshi V.; Prabhala R.; Fulciniti M.; Tai Y.T.; Treon S.P.; Goyal R.K.; Anderson K.C.; Munshi N.C.; Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006,108(8),2804-2810","journal-title":"Blood"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1158\/1078-0432.CCR-04-2273","volume":"11","author":"Nakazato T.","year":"2005","unstructured":"Nakazato T.; Ito K.; Ikeda Y.; Kizaki M.; Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res 2005,11(16),6040-6049","journal-title":"Clin Cancer Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.3892\/or.2013.2343","volume":"29","author":"Jin L.","year":"2013","unstructured":"Jin L.; Li C.; Xu Y.; Wang L.; Liu J.; Wang D.; Hong C.; Jiang Z.; Ma Y.; Chen Q.; Yu F.; Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol Rep 2013,29(5),1983-1990","journal-title":"Oncol Rep"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3892\/ijo.2012.1449","volume":"41","author":"Thakur V.S.","year":"2012","unstructured":"Thakur V.S.; Gupta K.; Gupta S.; Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int J Oncol 2012,41(1),353-361","journal-title":"Int J Oncol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/mc.22175","volume":"54","author":"Gordon M.W.","year":"2015","unstructured":"Gordon M.W.; Yan F.; Zhong X.; Mazumder P.B.; Xu-Monette Z.Y.; Zou D.; Young K.H.; Ramos K.S.; Li Y.; Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma. Mol Carcinog 2015,54(10),1060-1069","journal-title":"Mol Carcinog"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2165\/00003495-199753060-00001","volume":"53","author":"Fusco B.M.","year":"1997","unstructured":"Fusco B.M.; Giacovazzo M.; Peppers and pain. The promise of capsaicin. Drugs 1997,53(6),909-914","journal-title":"Drugs"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1309\/7AYY-VVH1-GQT5-J4R2","volume":"118","author":"Szallasi A.","year":"2002","unstructured":"Szallasi A.; Vanilloid (capsaicin) receptors in health and disease. Am J Clin Pathol 2002,118(1),110-121","journal-title":"Am J Clin Pathol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2217\/fon.10.117","volume":"6","author":"D\u00edaz-Laviada I.","year":"2010","unstructured":"D\u00edaz-Laviada I.; Effect of capsaicin on prostate cancer cells. Future Oncol 2010,6(10),1545-1550","journal-title":"Future Oncol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1158\/1078-0432.CCR-06-2575","volume":"13","author":"Bhutani M.","year":"2007","unstructured":"Bhutani M.; Pathak A.K.; Nair A.S.; Kunnumakkara A.B.; Guha S.; Sethi G.; Aggarwal B.B.; Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin Cancer Res 2007,13(10),3024-3032","journal-title":"Clin Cancer Res"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2174\/138945012804545470","volume":"13","author":"Donald G.","year":"2012","unstructured":"Donald G.; Hertzer K.; Eibl G.; Baicalein--an intriguing therapeutic phytochemical in pancreatic cancer. Curr Drug Targets 2012,13(14),1772-1776","journal-title":"Curr Drug Targets"},{"key":"ref=129","first-page":"133","volume":"24","author":"Lian J.P.","year":"2004","unstructured":"Lian J.P.; Word B.; Taylor S.; Hammons G.J.; Lyn-Cook B.D.; Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. Anticancer Res 2004,24(1),133-137","journal-title":"Anticancer Res"},{"key":"ref=130","first-page":"938","volume":"33","author":"Xu C.P.","year":"2012","unstructured":"Xu C.P.; Cai H.L.; He L.; Ma Z.; Liu S.Q.; [Effect of baicalein on proliferation and migration in multiple myeloma cell lines RPMI 8226 and U266 cells] Zhonghua Xue Ye Xue Za Zhi 2012,33(11),938-943","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1600-0609.2009.01365.x","volume":"84","author":"Liu S.","year":"2010","unstructured":"Liu S.; Ma Z.; Cai H.; Li Q.; Rong W.; Kawano M.; Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells. Eur J Haematol 2010,84(2),137-144","journal-title":"Eur J Haematol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1182\/blood-2004-10-3915","volume":"105","author":"Ma Z.","year":"2005","unstructured":"Ma Z.; Otsuyama K.; Liu S.; Abroun S.; Ishikawa H.; Tsuyama N.; Obata M.; Li F.J.; Zheng X.; Maki Y.; Miyamoto K.; Kawano M.M.; Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 2005,105(8),3312-3318","journal-title":"Blood"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00210-006-0090-1","volume":"374","author":"Rzeski W.","year":"2006","unstructured":"Rzeski W.; Stepulak A.; Szyma\u0144ski M.; Sifringer M.; Kaczor J.; Wejksza K.; Zdzisi\u0144ska B.; Kandefer-Szersze\u0144 M.; Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn Schmiedebergs Arch Pharmacol 2006,374(1),11-20","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ijc.25059","volume":"127","author":"Pandey M.K.","year":"2010","unstructured":"Pandey M.K.; Sung B.; Aggarwal B.B.; Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer 2010,127(2),282-292","journal-title":"Int J Cancer"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/aps.2012.102","volume":"33","author":"Yang L.J.","year":"2012","unstructured":"Yang L.J.; Chen Y.; He J.; Yi S.; Wen L.; Zhao J.; Zhang B.P.; Cui G.H.; Betulinic acid inhibits autophagic flux and induces apoptosis in human multiple myeloma cells in vitro. Acta Pharmacol Sin 2012,33(12),1542-1548","journal-title":"Acta Pharmacol Sin"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"17340","DOI":"10.1074\/jbc.M700890200","volume":"282","author":"Pandey M.K.","year":"2007","unstructured":"Pandey M.K.; Sandur S.K.; Sung B.; Sethi G.; Kunnumakkara A.B.; Aggarwal B.B.; Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J Biol Chem 2007,282(24),17340-17350","journal-title":"J Biol Chem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1124\/mol.108.052548","volume":"75","author":"Pandey M.K.","year":"2009","unstructured":"Pandey M.K.; Sung B.; Ahn K.S.; Aggarwal B.B.; Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol Pharmacol 2009,75(3),525-533","journal-title":"Mol Pharmacol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1002\/ijc.25868","volume":"129","author":"Sung B.","year":"2011","unstructured":"Sung B.; Cho S.G.; Liu M.; Aggarwal B.B.; Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling. Int J Cancer 2011,129(9),2062-2072","journal-title":"Int J Cancer"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"12915","DOI":"10.1007\/s13277-016-5194-8","volume":"37","author":"Kashyap D.","year":"2016","unstructured":"Kashyap D.; Mondal R.; Tuli H.S.; Kumar G.; Sharma A.K.; Molecular targets of gambogic acid in cancer: recent trends and advancements. Tumour Biol 2016,37(10),12915-12925","journal-title":"Tumour Biol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1158\/1940-6207.CAPR-10-0340","volume":"4","author":"Prasad S.","year":"2011","unstructured":"Prasad S.; Pandey M.K.; Yadav V.R.; Aggarwal B.B.; Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer Prev Res (Phila) 2011,4(7),1084-1094","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3892\/ol.2012.634","volume":"3","author":"Yang L.J.","year":"2012","unstructured":"Yang L.J.; Chen Y.; He J.; Yi S.; Wen L.; Zhao S.; Cui G.H.; Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS. Oncol Lett 2012,3(5),1159-1165","journal-title":"Oncol Lett"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejps.2013.02.018","volume":"49","author":"Lu N.","year":"2013","unstructured":"Lu N.; Hui H.; Yang H.; Zhao K.; Chen Y.; You Q.D.; Guo Q.L.; Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1\u03b1 pathway. Eur J Pharm Sci 2013,49(2),220-226","journal-title":"Eur J Pharm Sci"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.jcyt.2017.09.007","volume":"19","author":"Costa V.","year":"2017","unstructured":"Costa V.; Raimondi L.; Conigliaro A.; Salamanna F.; Carina V.; De Luca A.; Bellavia D.; Alessandro R.; Fini M.; Giavaresi G.; Hypoxia-inducible factor 1A may regulate the commitment of mesenchymal stromal cells toward angio-osteogenesis by mirna-675-5P. Cytotherapy 2017,19(12),1412-1425","journal-title":"Cytotherapy"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.18632\/oncotarget.1747","volume":"5","author":"Raimondi L.","year":"2014","unstructured":"Raimondi L.; Amodio N.; Di Martino M.T.; Altomare E.; Leotta M.; Caracciolo D.; Gull\u00e0 A.; Neri A.; Taverna S.; D\u2019Aquila P.; Alessandro R.; Giordano A.; Tagliaferri P.; Tassone P.; Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget 2014,5(10),3039-3054","journal-title":"Oncotarget"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/cas.12458","volume":"105","author":"Wang F.","year":"2014","unstructured":"Wang F.; Zhang W.; Guo L.; Bao W.; Jin N.; Liu R.; Liu P.; Wang Y.; Guo Q.; Chen B.; Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1\u03b1\/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase\/Akt\/mammalian target protein of rapamycin pathway in multiple myeloma cells. Cancer Sci 2014,105(8),1063-1070","journal-title":"Cancer Sci"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.exphem.2014.07.261","volume":"42","author":"Pandey M.K.","year":"2014","unstructured":"Pandey M.K.; Kale V.P.; Song C.; Sung S.S.; Sharma A.K.; Talamo G.; Dovat S.; Amin S.G.; Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways. Exp Hematol 2014,42(10),883-896","journal-title":"Exp Hematol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"Holick M.F.","year":"2007","unstructured":"Holick M.F.; Vitamin D deficiency. N Engl J Med 2007,357(3),266-281","journal-title":"N Engl J Med"},{"key":"ref=148","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-016-0331-2","author":"Bellavia D.","year":"2016","unstructured":"Bellavia D.; Costa V.; De Luca A.; Maglio M.; Pagani S.; Fini M.; Giavaresi G.; Vitamin D level between calcium-phosphorus homeostasis and immune system: new perspective in osteoporosis. Curr Osteoporos Rep 2016","journal-title":"Curr Osteoporos Rep"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1365-2141.2008.07214.x","volume":"142","author":"Badros A.","year":"2008","unstructured":"Badros A.; Goloubeva O.; Terpos E.; Milliron T.; Baer M.R.; Streeten E.; Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol 2008,142(3),492-494","journal-title":"Br J Haematol"},{"key":"ref=150","first-page":"533","volume":"20","author":"Park W.H.","year":"2002","unstructured":"Park W.H.; Seol J.G.; Kim E.S.; Binderup L.; Koeffler H.P.; Kim B.K.; Lee Y.Y.; The induction of apoptosis by a combined 1,25(OH)2D3 analog, EB1089 and TGF-beta1 in NCI-H929 multiple myeloma cells. Int J Oncol 2002,20(3),533-542","journal-title":"Int J Oncol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1365-2141.2005.05710.x","volume":"130","author":"Calvani N.","year":"2005","unstructured":"Calvani N.; Cafforio P.; Silvestris F.; Dammacco F.; Functional osteoclast-like transformation of cultured human myeloma cell lines. Br J Haematol 2005,130(6),926-938","journal-title":"Br J Haematol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.yexcr.2017.06.023","volume":"358","author":"Cafforio P.","year":"2017","unstructured":"Cafforio P.; D\u2019Oronzo S.; Felici C.; Sigala S.; Fragni M.; Silvestris F.; 1,25(OH)2 vitamin D(3) contributes to osteoclast-like trans-differentiation of malignant plasma cells. Exp Cell Res 2017,358(2),260-268","journal-title":"Exp Cell Res"},{"key":"ref=153","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/718539","author":"Tangen J.M.","year":"2015","unstructured":"Tangen J.M.; Tierens A.; Caers J.; Binsfeld M.; Olstad O.K.; Tr\u00f8seid A.M.; Wang J.; Tj\u00f8nnfjord G.E.; Hetland G.; Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study. BioMed Res Int 2015","journal-title":"BioMed Res Int"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5650\/jos.56.179","volume":"56","author":"Murakawa K.","year":"2007","unstructured":"Murakawa K.; Fukunaga K.; Tanouchi M.; Hosokawa M.; Hossain Z.; Takahashi K.; Therapy of myeloma in vivo using marine phospholipid in combination with Agaricus blazei Murill as an immune respond activator. J Oleo Sci 2007,56(4),179-188","journal-title":"J Oleo Sci"},{"key":"ref=155","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2059825","volume":"2017","author":"Tangen J.M.","year":"2017","unstructured":"Tangen J.M.; Holien T.; Mirlashari M.R.; Misund K.; Hetland G.; Cytotoxic Effect on Human Myeloma Cells and Leukemic Cells by the Agaricus blazei Murill Based Mushroom Extract, Andosan\u2122. BioMed Res Int 2017,2017","journal-title":"BioMed Res Int"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/carcin\/bgq215","volume":"32","author":"Singh T.","year":"2011","unstructured":"Singh T.; Vaid M.; Katiyar N.; Sharma S.; Katiyar S.K.; Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E and prostaglandin E receptors. Carcinogenesis 2011,32(1),86-92","journal-title":"Carcinogenesis"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/aps.2012.161","volume":"34","author":"Hu H.Y.","year":"2013","unstructured":"Hu H.Y.; Li K.P.; Wang X.J.; Liu Y.; Lu Z.G.; Dong R.H.; Guo H.B.; Zhang M.X.; Set9, NF-\u03baB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells. Acta Pharmacol Sin 2013,34(1),157-166","journal-title":"Acta Pharmacol Sin"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.critrevonc.2017.05.008","volume":"116","author":"Ayati S.H.","year":"2017","unstructured":"Ayati S.H.; Fazeli B.; Momtazi-Borojeni A.A.; Cicero A.F.G.; Pirro M.; Sahebkar A.; Regulatory effects of berberine on microRNome in cancer and other conditions. Crit Rev Oncol Hematol 2017,116,147-158","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/15476286.2015.1017219","volume":"12","author":"Feng M.","year":"2015","unstructured":"Feng M.; Luo X.; Gu C.; Li Y.; Zhu X.; Fei J.; Systematic analysis of berberine-induced signaling pathway between miRNA clusters and mRNAs and identification of mir-99a \u223c 125b cluster function by seed-targeting inhibitors in multiple myeloma cells. RNA Biol 2015,12(1),82-91","journal-title":"RNA Biol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1752-0509-8-82","volume":"8","author":"Luo X.","year":"2014","unstructured":"Luo X.; Gu J.; Zhu R.; Feng M.; Zhu X.; Li Y.; Fei J.; Integrative analysis of differential miRNA and functional study of miR-21 by seed-targeting inhibition in multiple myeloma cells in response to berberine. BMC Syst Biol 2014,8,82","journal-title":"BMC Syst Biol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10142-016-0519-7","volume":"17","author":"Gu C.","year":"2017","unstructured":"Gu C.; Li T.; Yin Z.; Chen S.; Fei J.; Shen J.; Zhang Y.; Integrative analysis of signaling pathways and diseases associated with the miR-106b\/25 cluster and their function study in berb\ufefferine-induced multiple myeloma cells. Funct Integr Genomics 2017,17(2-3),253-262","journal-title":"Funct Integr Genomics"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1021\/np030304+","volume":"67","author":"Cuendet M.","year":"2004","unstructured":"Cuendet M.; Pezzuto J.M.; Antitumor activity of bruceantin: an old drug with new promise. J Nat Prod 2004,67(2),269-272","journal-title":"J Nat Prod"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1158\/1078-0432.CCR-0362-3","volume":"10","author":"Cuendet M.","year":"2004","unstructured":"Cuendet M.; Christov K.; Lantvit D.D.; Deng Y.; Hedayat S.; Helson L.; McChesney J.D.; Pezzuto J.M.; Multiple myeloma regression mediated by bruceantin. Clin Cancer Res 2004,10(3),1170-1179","journal-title":"Clin Cancer Res"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1080\/15384047.2016.1210737","volume":"17","author":"Issa M.E.","year":"2016","unstructured":"Issa M.E.; Berndt S.; Carpentier G.; Pezzuto J.M.; Cuendet M.; Bruceantin inhibits multiple myeloma cancer stem cell proliferation. Cancer Biol Ther 2016,17(9),966-975","journal-title":"Cancer Biol Ther"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13148-017-0319-5","volume":"9","author":"Issa M.E.","year":"2017","unstructured":"Issa M.E.; Takhsha F.S.; Chirumamilla C.S.; Perez-Novo C.; Vanden Berghe W.; Cuendet M.; Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics 2017,9,17","journal-title":"Clin Epigenetics"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1055\/s-0032-1328554","volume":"79","author":"Yu Q.","year":"2013","unstructured":"Yu Q.; Chen B.; Zhang X.; Qian W.; Ye B.; Zhou Y.; Arsenic trioxide-enhanced, matrine-induced apoptosis in multiple myeloma cell lines. Planta Med 2013,79(9),775-781","journal-title":"Planta Med"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s11655-015-1975-y","volume":"21","author":"Zhou Y.H.","year":"2015","unstructured":"Zhou Y.H.; Feng J.Y.; You L.S.; Meng H.T.; Qian W.B.; Matrine and CYC116 synergistically inhibit growth and induce apoptosis in multiple myeloma cells. Chin J Integr Med 2015,21(8),635-639","journal-title":"Chin J Integr Med"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s12013-012-9492-5","volume":"66","author":"Rao P.S.","year":"2013","unstructured":"Rao P.S.; Prasad M.N.; Strychnos nux-vomica root extract induces apoptosis in the human multiple myeloma cell line-U266B1. Cell Biochem Biophys 2013,66(3),443-450","journal-title":"Cell Biochem Biophys"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.fct.2008.10.027","volume":"47","author":"Rao P.S.","year":"2009","unstructured":"Rao P.S.; Ramanadham M.; Prasad M.N.; Anti-proliferative and cytotoxic effects of Strychnos nux-vomica root extract on human multiple myeloma cell line - RPMI 8226. Food Chem Toxicol 2009,47(2),283-288","journal-title":"Food Chem Toxicol"},{"key":"ref=170","doi-asserted-by":"publisher","DOI":"10.3390\/nu8100611","volume":"8","author":"Tibullo D.","year":"2016","unstructured":"Tibullo D.; Caporarello N.; Giallongo C.; Anfuso C.D.; Genovese C.; Arlotta C.; Puglisi F.; Parrinello N.L.; Bramanti V.; Romano A.; Lupo G.; Toscano V.; Avola R.; Brundo M.V.; Di Raimondo F.; Raccuia S.A.; Antiproliferative and antiangiogenic effects of punica granatum juice (PGJ) in Multiple Myeloma (MM). Nutrients 2016,8(10)","journal-title":"Nutrients"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s13277-015-3962-5","volume":"37","author":"Kiraz Y.","year":"2016","unstructured":"Kiraz Y.; Neergheen-Bhujun V.S.; Rummun N.; Baran Y.; Apoptotic effects of non-edible parts of Punica granatum on human multiple myeloma cells. Tumour Biol 2016,37(2),1803-1815","journal-title":"Tumour Biol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.18632\/oncotarget.6796","volume":"7","author":"Fu R.","year":"2016","unstructured":"Fu R.; Chen Y.; Wang X.P.; An T.; Tao L.; Zhou Y.X.; Huang Y.J.; Chen B.A.; Li Z.Y.; You Q.D.; Guo Q.L.; Wu Z.Q.; Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc\/VHL\/HIF-1\u03b1 signaling axis. Oncotarget 2016,7(5),5715-5727","journal-title":"Oncotarget"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.7314\/APJCP.2013.14.12.7179","volume":"14","author":"Lin M.G.","year":"2013","unstructured":"Lin M.G.; Liu L.P.; Li C.Y.; Zhang M.; Chen Y.; Qin J.; Gu Y.Y.; Li Z.; Wu X.L.; Mo S.L.; Scutellaria extract decreases the proportion of side population cells in a myeloma cell line by down-regulating the expression of ABCG2 protein. Asian Pac J Cancer Prev 2013,14(12),7179-7186","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lfs.2012.10.023","volume":"92","author":"Zhang M.","year":"2013","unstructured":"Zhang M.; Liu L.P.; Chen Y.; Tian X.Y.; Qin J.; Wang D.; Li Z.; Mo S.L.; Wogonin induces apoptosis in RPMI 8226, a human myeloma cell line, by downregulating phospho-Akt and overexpressing Bax. Life Sci 2013,92(1),55-62","journal-title":"Life Sci"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"2073S-85S","DOI":"10.1093\/jn\/130.8.2073S","volume":"130","author":"Scalbert A.","year":"2000","unstructured":"Scalbert A.; Williamson G.; Dietary intake and bioavailability of polyphenols. J Nutr 2000,130(8S Suppl),2073S-85S","journal-title":"J Nutr"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.numecd.2009.10.011","volume":"21","author":"Angelone T.","year":"2011","unstructured":"Angelone T.; Pasqua T.; Di Majo D.; Quintieri A.M.; Filice E.; Amodio N.; Tota B.; Giammanco M.; Cerra M.C.; Distinct signalling mechanisms are involved in the dissimilar myocardial and coronary effects elicited by quercetin and myricetin, two red wine flavonols. Nutr Metab Cardiovasc Dis 2011,21(5),362-371","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.canlet.2013.12.008","volume":"345","author":"Lee J.H.","year":"2014","unstructured":"Lee J.H.; Chiang S.Y.; Nam D.; Chung W.S.; Lee J.; Na Y.S.; Sethi G.; Ahn K.S.; Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases. Cancer Lett 2014,345(1),140-148","journal-title":"Cancer Lett"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.canlet.2014.08.002","volume":"354","author":"Kim S.M.","year":"2014","unstructured":"Kim S.M.; Lee J.H.; Sethi G.; Kim C.; Baek S.H.; Nam D.; Chung W.S.; Kim S.H.; Shim B.S.; Ahn K.S.; Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells. Cancer Lett 2014,354(1),153-163","journal-title":"Cancer Lett"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/1541-7786.MCR-08-0154","volume":"7","author":"Kunnumakkara A.B.","year":"2009","unstructured":"Kunnumakkara A.B.; Nair A.S.; Sung B.; Pandey M.K.; Aggarwal B.B.; Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol Cancer Res 2009,7(1),118-128","journal-title":"Mol Cancer Res"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.fct.2011.03.021","volume":"49","author":"Park S.","year":"2011","unstructured":"Park S.; Lee H.J.; Jeong S.J.; Song H.S.; Kim M.; Lee H.J.; Lee E.O.; Kim D.H.; Ahn K.S.; Kim S.H.; Inhibition of JAK1\/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells. Food Chem Toxicol 2011,49(6),1367-1372","journal-title":"Food Chem Toxicol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.biopha.2016.07.045","volume":"83","author":"Sun X.","year":"2016","unstructured":"Sun X.; Liao W.; Wang J.; Wang P.; Gao H.; Wang M.; Xu C.; Zhong Y.; Ding Y.; CSTMP induces apoptosis and mitochondrial dysfunction in human myeloma RPMI8226 cells via CHOP-dependent endoplasmic reticulum stress. Biomed Pharmacother 2016,83,776-784","journal-title":"Biomed Pharmacother"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1158\/1535-7163.MCT-06-0605","volume":"6","author":"Muto A.","year":"2007","unstructured":"Muto A.; Hori M.; Sasaki Y.; Saitoh A.; Yasuda I.; Maekawa T.; Uchida T.; Asakura K.; Nakazato T.; Kaneda T.; Kizaki M.; Ikeda Y.; Yoshida T.; Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 2007,6(3),987-994","journal-title":"Mol Cancer Ther"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/jcb.23077","volume":"112","author":"Lee J.C.","year":"2011","unstructured":"Lee J.C.; Ahn K.S.; Jeong S.J.; Jung J.H.; Kwon T.R.; Rhee Y.H.; Kim S.H.; Kim S.Y.; Yoon H.J.; Zhu S.; Chen C.Y.; Kim S.H.; Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells. J Cell Biochem 2011,112(6),1552-1562","journal-title":"J Cell Biochem"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1586\/17474086.2013.874943","volume":"7","author":"Terpos E.","year":"2014","unstructured":"Terpos E.; Berenson J.; Raje N.; Roodman G.D.; Management of bone disease in multiple myeloma. Expert Rev Hematol 2014,7(1),113-125","journal-title":"Expert Rev Hematol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1053\/j.seminoncol.2010.06.009","volume":"37","author":"Berenson J.R.","year":"2010","unstructured":"Berenson J.R.; Therapeutic options in the management of myeloma bone disease. Semin Oncol 2010,37(Suppl. 1),S20-S29","journal-title":"Semin Oncol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.2174\/092986711796391660","volume":"18","author":"Coluzzi F.","year":"2011","unstructured":"Coluzzi F.; Di Bussolo E.; Mandatori I.; Mattia C.; Bone metastatic disease: taking aim at new therapeutic targets. Curr Med Chem 2011,18(20),3093-3115","journal-title":"Curr Med Chem"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/JPR.S83490","volume":"8","author":"Coluzzi F.","year":"2015","unstructured":"Coluzzi F.; Raffa R.B.; Pergolizzi J.; Rocco A.; Locarini P.; Cenfra N.; Cimino G.; Mattia C.; Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res 2015,8,229-238","journal-title":"J Pain Res"},{"key":"ref=188","first-page":"289","volume":"102","author":"Coluzzi F.","year":"2011","unstructured":"Coluzzi F.; Berti M.; Change Pain: changing the approach to chronic pain. Minerva Med 2011,102(4),289-307","journal-title":"Minerva Med"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1185\/03007995.2014.925439","volume":"30","author":"M\u00fcller-Schwefe G.","year":"2014","unstructured":"M\u00fcller-Schwefe G.; Ahlbeck K.; Aldington D.; Alon E.; Coaccioli S.; Coluzzi F.; Huygen F.; Jaksch W.; Kalso E.; Kocot-K\u0119pska M.; Kress H.G.; Mangas A.C.; Ferri C.M.; Morlion B.; Nicolaou A.; Hern\u00e1ndez C.P.; Pergolizzi J.; Sch\u00e4fer M.; Sich\u00e8re P.; Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements. Curr Med Res Opin 2014,30(9),1895-1908","journal-title":"Curr Med Res Opin"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3390\/medicines2040328","volume":"2","author":"Zhou Z.W.","year":"2015","unstructured":"Zhou Z.W.; Zhou S.F.; Editorial for Special Issue on Herbal Medicines and Natural Products. Medicines (Basel) 2015,2(4),328-330","journal-title":"Medicines (Basel)"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00018-008-7452-4","volume":"65","author":"Hatcher H.","year":"2008","unstructured":"Hatcher H.; Planalp R.; Cho J.; Torti F.M.; Torti S.V.; Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008,65(11),1631-1652","journal-title":"Cell Mol Life Sci"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ptr.2070","volume":"21","author":"Sharma S.","year":"2007","unstructured":"Sharma S.; Chopra K.; Kulkarni S.K.; Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res 2007,21(3),278-283","journal-title":"Phytother Res"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ptr.2662","volume":"23","author":"Mittal N.","year":"2009","unstructured":"Mittal N.; Joshi R.; Hota D.; Chakrabarti A.; Evaluation of antihyperalgesic effect of curcumin on formalin-induced orofacial pain in rat. Phytother Res 2009,23(4),507-512","journal-title":"Phytother Res"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1124\/jpet.117.245068","volume":"365","author":"El Nebrisi E.G.","year":"2018","unstructured":"El Nebrisi E.G.; Bagdas D.; Toma W.; Al Samri H.; Brodzik A.; Alkhlaif Y.; Yang K.S.; Howarth F.C.; Damaj I.M.; Oz M.; Curcumin acts as a positive allosteric modulator of \u03b17-nicotinic acetylcholine receptors and reverses nociception in mouse models of inflammatory pain. J Pharmacol Exp Ther 2018,365(1),190-200","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/WNR.0b013e328314decb","volume":"20","author":"Matsushita Y.","year":"2009","unstructured":"Matsushita Y.; Ueda H.; Curcumin blocks chronic morphine analgesic tolerance and brain-derived neurotrophic factor upregulation. Neuroreport 2009,20(1),63-68","journal-title":"Neuroreport"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jpain.2012.10.005","volume":"14","author":"Liang D.Y.","year":"2013","unstructured":"Liang D.Y.; Li X.; Clark J.D.; Epigenetic regulation of opioid-induced hyperalgesia, dependence, and tolerance in mice. J Pain 2013,14(1),36-47","journal-title":"J Pain"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1745-7254.2005.00081.x","volume":"26","author":"Liu H.L.","year":"2005","unstructured":"Liu H.L.; Chen Y.; Cui G.H.; Zhou J.F.; Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol Sin 2005,26(5),603-609","journal-title":"Acta Pharmacol Sin"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1742-7843.2007.00142.x","volume":"101","author":"Chen Y.","year":"2007","unstructured":"Chen Y.; Shu W.; Chen W.; Wu Q.; Liu H.; Cui G.; Curcumin, both histone deacetylase and p300\/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin Pharmacol Toxicol 2007,101(6),427-433","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.neuro.2011.08.001","volume":"32","author":"Abdel-Zaher A.O.","year":"2011","unstructured":"Abdel-Zaher A.O.; Abdel-Rahman M.S.; Elwasei F.M.; Protective effect of Nigella sativa oil against tramadol-induced tolerance and dependence in mice: role of nitric oxide and oxidative stress. Neurotoxicology 2011,32(6),725-733","journal-title":"Neurotoxicology"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s11064-010-0215-2","volume":"35","author":"Abdel-Zaher A.O.","year":"2010","unstructured":"Abdel-Zaher A.O.; Abdel-Rahman M.S.; ELwasei, F.M. Blockade of nitric oxide overproduction and oxidative stress by Nigella sativa oil attenuates morphine-induced tolerance and dependence in mice. Neurochem Res 2010,35(10),1557-1565","journal-title":"Neurochem Res"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/ptr.5073","volume":"28","author":"Tabatabai S.M.","year":"2014","unstructured":"Tabatabai S.M.; Dashti S.; Doosti F.; Hosseinzadeh H.; Phytotherapy of opioid dependence and withdrawal syndrome: a review. Phytother Res 2014,28(6),811-830","journal-title":"Phytother Res"},{"key":"ref=202","first-page":"8","volume":"82","author":"Amin B.","year":"2016","unstructured":"Amin B.; Hosseinzadeh H.; Black cumin (nigella sativa) and its active constituent, thymoquinone: an overview on the analgesic and anti-inflammatory effects. Planta Med 2016,82(1-2),8-16","journal-title":"Planta Med"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.intimp.2015.06.023","volume":"28","author":"Majdalawieh A.F.","year":"2015","unstructured":"Majdalawieh A.F.; Fayyad M.W.; Immunomodulatory and anti-inflammatory action of Nigella sativa and thymoquinone: A comprehensive review. Int Immunopharmacol 2015,28(1),295-304","journal-title":"Int Immunopharmacol"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3109\/09637486.2013.798268","volume":"64","author":"Usta C.","year":"2013","unstructured":"Usta C.; Ozdemir S.; Schiariti M.; Puddu P.E.; The pharmacological use of ellagic acid-rich pomegranate fruit. Int J Food Sci Nutr 2013,64(7),907-913","journal-title":"Int J Food Sci Nutr"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12906-017-1555-0","volume":"17","author":"BenSaad L.A.","year":"2017","unstructured":"BenSaad L.A.; Kim K.H.; Quah C.C.; Kim W.R.; Shahimi M.; Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A","journal-title":"BMC Complement Altern Med"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ejphar.2014.08.024","volume":"741","author":"Mansouri M.T.","year":"2014","unstructured":"Mansouri M.T.; Naghizadeh B.; Ghorbanzadeh B.; Ellagic acid enhances morphine analgesia and attenuates the development of morphine tolerance and dependence in mice. Eur J Pharmacol 2014,741,272-280","journal-title":"Eur J Pharmacol"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejphar.2013.03.031","volume":"707","author":"Taghi Mansouri M.","year":"2013","unstructured":"Taghi Mansouri M.; Naghizadeh B.; Ghorbanzadeh B.; Farbood Y.; Central and peripheral antinociceptive effects of ellagic acid in different animal models of pain. Eur J Pharmacol 2013,707(1-3),46-53","journal-title":"Eur J Pharmacol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/abbs\/gmx103","volume":"49","author":"Zhu H.","year":"2017","unstructured":"Zhu H.; Ding J.; Wu J.; Liu T.; Liang J.; Tang Q.; Jiao M.; Resveratrol attenuates bone cancer pain through regulating the expression levels of ASIC3 and activating cell autophagy. Acta Biochim Biophys Sin (Shanghai) 2017,49(11),1008-1014","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s11011-017-0033-1","volume":"32","author":"Wang W.","year":"2017","unstructured":"Wang W.; Yu Y.; Li J.; Wang L.; Li Z.; Zhang C.; Zhen L.; Ding L.; Wang G.; Sun X.; Xu Y.; The analgesic effect of trans-resveratrol is regulated by calcium channels in the hippocampus of mice. Metab Brain Dis 2017,32(4),1311-1321","journal-title":"Metab Brain Dis"},{"key":"ref=210","doi-asserted-by":"publisher","DOI":"10.1177\/1744806917697010","volume":"13","author":"Takehana S.","year":"2017","unstructured":"Takehana S.; Kubota Y.; Uotsu N.; Yui K.; Iwata K.; Shimazu Y.; Takeda M.; The dietary constituent resveratrol suppresses nociceptive neurotransmission via the NMDA receptor. Mol Pain 2017,13","journal-title":"Mol Pain"},{"key":"ref=211","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17101702","volume":"17","author":"Takeda M.","year":"2016","unstructured":"Takeda M.; Takehana S.; Sekiguchi K.; Kubota Y.; Shimazu Y.; Modulatory mechanism of nociceptive neuronal activity by dietary constituent resveratrol. Int J Mol Sci 2016,17(10)","journal-title":"Int J Mol Sci"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jfma.2015.05.010","volume":"115","author":"Tsai R.Y.","year":"2016","unstructured":"Tsai R.Y.; Wang J.C.; Chou K.Y.; Wong C.S.; Cherng C.H.; Resveratrol reverses morphine-induced neuroinflammation in morphine-tolerant rats by reversal HDAC1 expression. J Formos Med Assoc 2016,115(6),445-454","journal-title":"J Formos Med Assoc"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.pbb.2008.05.024","volume":"90","author":"P\u00e9rez-Severiano F.","year":"2008","unstructured":"P\u00e9rez-Severiano F.; Berm\u00fadez-Oca\u00f1a D.Y.; L\u00f3pez-S\u00e1nchez P.; R\u00edos C.; Granados-Soto V.; Spinal nerve ligation reduces nitric oxide synthase activity and expression: effect of resveratrol. Pharmacol Biochem Behav 2008,90(4),742-747","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=214","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091406","volume":"9","author":"Silva A.M.","year":"2014","unstructured":"Silva A.M.; Oliveira M.I.; Sette L.; Almeida C.R.; Oliveira M.J.; Barbosa M.A.; Santos S.G.; Resveratrol as a natural anti-tumor necrosis factor-\u03b1 molecule: implications to dendritic cells and their crosstalk with mesenchymal stromal cells. PLoS One 2014,9(3)","journal-title":"PLoS One"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/163364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T18:40:58Z","timestamp":1584988858000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/163364\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":214,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,18]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666180629153141","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}